Becketts advises Telix Pharmaceuticals on acquisition of IsoTherapeutics (U.S.)

Telix is an ASX-listed (ASX: TLX) biopharmaceuticals company focused on the development and commercialisation of diagnostic and therapeutic radiopharmaceuticals and associated medical devices. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Europe and Japan.

IsoTherapeutics is specialty radiopharmaceutical development and bioconjugation firm that provides development and manufacturing services to companies in the radiopharmaceutical industry. The acquisition further enhances Telix’s in-house development capabilities and its manufacturing presence in the United States.​

The Becketts team which advised Telix on the transaction included Alex Bean and Nick Golding, Partners, and Brad Papaluca, Lawyer. Telix’s US lawyers on the transaction were Sidley Austin LLP, with the team led by Sara Garcia Duran, Partner and Adrienn Portnoy, Associate.